Predicting allopurinol response in patients with gout

被引:43
|
作者
Wright, Daniel F. B. [1 ]
Duffull, Stephen B. [1 ]
Merriman, Tony R. [2 ]
Dalbeth, Nicola [3 ]
Barclay, Murray L. [4 ,5 ]
Stamp, Lisa K. [4 ]
机构
[1] Univ Otago, Sch Pharm, POB 56, Dunedin 9054, New Zealand
[2] Univ Otago, Dept Biochem, Dunedin 9054, New Zealand
[3] Univ Auckland, Dept Med, Auckland 1, New Zealand
[4] Univ Otago, Dept Med, Christchurch, New Zealand
[5] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand
关键词
allopurinol; gout; nonmem; pharmacokinetic-pharmacodynamics; CONTROL SAMPLE SETS; SERUM URIC-ACID; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; VS; SEQUENTIAL-ANALYSIS; HYPERSENSITIVITY SYNDROME; CREATININE CLEARANCE; PLASMA OXYPURINOL; ADVERSE-REACTIONS; HEALTHY-SUBJECTS;
D O I
10.1111/bcp.12799
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsThe primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of 0.36mmoll(-1). MethodsA population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. ResultsThe urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. ConclusionsContrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
引用
收藏
页码:277 / 289
页数:13
相关论文
共 50 条
  • [1] WITHDRAWAL OF ALLOPURINOL IN PATIENTS WITH GOUT
    SCOTT, JT
    LOEBL, WY
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1973, 9 (08): : 1112 - 1113
  • [2] WITHDRAWAL OF ALLOPURINOL IN PATIENTS WITH GOUT
    LOEBL, WY
    SCOTT, JT
    ANNALS OF THE RHEUMATIC DISEASES, 1974, 33 (04) : 304 - 307
  • [3] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [4] PREDICTORS OF ALLOPURINOL ADHERENCE IN PATIENTS WITH GOUT
    Singh, J. A.
    VALUE IN HEALTH, 2015, 18 (03) : A249 - A249
  • [5] EVALUATION OF ALLOPURINOL USE IN PATIENTS WITH GOUT
    ZELL, SC
    CARMICHAEL, JM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1989, 46 (09): : 1813 - 1816
  • [6] EFFECTS OF ALLOPURINOL INTERRUPTION IN PATIENTS WITH GOUT
    不详
    SEMAINE DES HOPITAUX THERAPEUTIQUE, 1975, 51 (10): : 579 - 580
  • [7] Allopurinol Adherence in US Patients With Gout
    Riggs, Kevin R.
    Richman, Joshua S.
    Cherrington, Andrea L.
    Singh, Jasvinder A.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2025, 31 (02) : 83 - 86
  • [8] Individualising the dose of allopurinol in patients with gout
    Kannangara, Diluk R. W.
    Graham, Garry G.
    Wright, Daniel F. B.
    Stocker, Sophie L.
    Portek, Ian
    Pile, Kevin D.
    Barclay, Murray L.
    Williams, Kenneth M.
    Stamp, Lisa K.
    Day, Richard O.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (09) : 2015 - 2026
  • [9] ALLOPURINOL IN TREATMENT OF URAEMIC PATIENTS WITH GOUT
    WILSON, JD
    SIMMONDS, HA
    NORTH, JDK
    ANNALS OF THE RHEUMATIC DISEASES, 1967, 26 (02) : 136 - +
  • [10] TREATING GOUT PATIENTS WITH ALLOPURINOL: A CONCENTRATION- OR DOSE-RESPONSE APPROACH?
    Kannangara, D.
    Graham, G.
    Wright, D.
    Barclay, M.
    Stamp, L.
    Williams, K.
    Day, R.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 13 - 13